Seizinger Bernd R. 4

What Happened
Bernd R. Seizinger, a director of Oncolytics Biotech Inc. (ONCY), purchased a total of 100,000 common shares in two open-market/private transactions on Feb 11–12, 2026. He bought 60,000 shares at $0.83 per share (reported value $49,590) on Feb 11 and 40,000 shares at $0.85 per share (reported value $33,864) on Feb 12, for a combined reported outlay of $83,454. These were purchases (Form 4 code "P"), which many investors view as a modestly positive signal because insiders bought stock rather than sold.

Key Details

• Transaction dates and prices:
  • Feb 11, 2026 — 60,000 shares at $0.83 (reported $49,590)
  • Feb 12, 2026 — 40,000 shares at $0.85 (reported $33,864)
• Total shares acquired: 100,000; total reported cost: $83,454
• Shares owned after transaction: Not specified in the information provided in your summary (check the full Form 4 for post-transaction holdings)
• Filing/timeliness: Form filed Feb 13, 2026 — appears to be within the standard two-business-day Form 4 reporting window
• Footnotes/plans: No 10b5-1 plan, tax-withholding, or other footnotes were noted in the summary provided

Context
Purchases by company directors can be interpreted as a signal of confidence, but they are only one data point. This transaction is relatively small in dollar terms (~$83K) compared with most public-company market caps, so weigh it alongside company fundamentals, recent news, and other insider activity. For full details (exact post-transaction ownership, any footnotes, and the official filing), review the SEC Form 4 accession 0001493152-26-006548.